Chenhe Yi
Impact in
- Hepatology top 10%
- Hepatocellular Carcinoma Treatment and Prognosis
-
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Papers in
- Co-authors
- Hu‐Liang Jia (3 shared papers)Jing Lin (7 shared papers)Jinhong Chen (9 shared papers)Weiqing Shao (7 shared papers)Lirong Chen (2 shared papers)Zhifei Lin (3 shared papers)Lu Lu (2 shared papers)Lun–Xiu Qin (1 shared paper)
In The Last Decade
Chenhe Yi
15 papers receiving 351 citations
Chenhe Yi's Hit Papers
Peers
Comparison fields: 5 of 46
- Hepatology 111
- Oncology 157
- Cancer Research 81
- Pathology and Forensic Medicine 70
- Immunology 75
Countries citing papers authored by Chenhe Yi
This map shows the geographic impact of Chenhe Yi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chenhe Yi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chenhe Yi more than expected).
Fields of papers citing papers by Chenhe Yi
This network shows the impact of papers produced by Chenhe Yi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chenhe Yi. The network helps show where Chenhe Yi may publish in the future.
Co-authors
The 25 scholars most cited alongside Chenhe Yi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti–Programmed Cell Death‐1 in HCC Hit paper breakdown → | 2021 | 212 |
| 2 | 2018 | 47 | |
| 3 | 2024 | 17 | |
| 4 | 2018 | 14 | |
| 5 | 2022 | 12 | |
| 6 | 2023 | 10 | |
| 7 | 2020 | 10 | |
| 8 | 2023 | 8 | |
| 9 | 2022 | 7 | |
| 10 | 2022 | 6 | |
| 11 | 2022 | 5 | |
| 12 | 2024 | 2 | |
| 13 | 2024 | 2 | |
| 14 | 2025 | 1 | |
| 15 | 2025 | 1 | |
| 16 | 2025 | 0 |
About Chenhe Yi
Chenhe Yi is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Molecular Biology and Pathology and Forensic Medicine, having authored 16 papers that have together received 354 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Ferroptosis and cancer prognosis (3 papers), interferon and immune responses (3 papers), Cancer Mechanisms and Therapy (3 papers), Cancer, Lipids, and Metabolism (2 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Cancer Immunotherapy and Biomarkers (2 papers) and Cholesterol and Lipid Metabolism (2 papers). The work is most often cited by research in Hepatology (111 citations), Oncology (157 citations), Cancer Research (81 citations), Pathology and Forensic Medicine (70 citations) and Immunology (75 citations). Chenhe Yi has collaborated with scholars based in China and Belgium. Frequent co-authors include Hu‐Liang Jia, Jing Lin, Jinhong Chen, Weiqing Shao, Lirong Chen, Zhifei Lin, Lu Lu, Lun–Xiu Qin, Jubo Zhang and Lu Liu. Their work appears in journals such as Clinical & Experimental Metastasis, Scientific Reports, Journal of Surgical Research, Cancer Immunology Immunotherapy and OncoTargets and Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.